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Parkinson’s disease (PD) affects millions of patients worldwide and is characterized by alpha-
synuclein aggregation in dopamine neurons. Molecular tweezers have shown high potential
as anti-aggregation agents targeting positively charged residues of proteins undergoing
amyloidogenic processes. Here we report that the molecular tweezer CLR01 decreased
aggregation and toxicity in induced pluripotent stem cell-derived dopaminergic cultures
treated with PD brain protein extracts. In microfluidic devices CLR01 reduced alpha-synuclein
aggregation in cell somas when axonal terminals were exposed to alpha-synuclein oligomers.
We then tested CLR01 in vivo in a humanized alpha-synuclein overexpressing mouse model;
mice treated at 12 months of age when motor defects are mild exhibited an improvement in
motor defects and a decreased oligomeric alpha-synuclein burden. Finally, CLR01 reduced
alpha-synuclein-associated pathology in mice injected with alpha-synuclein aggregates into
the striatum or substantia nigra. Taken together, these results highlight CLR01 as a disease-
modifying therapy for PD and support further clinical investigation.
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Parkinson’s disease (PD) is the second most common neu-rodegenerative disorder affecting millions of peopleworldwide presenting with resting tremor, altered gait,
bradykinesia, rigidity, hyposmia, constipation, and rapid eye
movement sleep behavior disorder1. Classic neuropathological
examination of PD patient post-mortem tissue shows a loss of
dopaminergic neurons in the substantia nigra (SN) pars compacta
(SNc) of the midbrain, as well as an accumulation of α-synuclein
(α-syn) in inclusions known as Lewy bodies (LBs) and Lewy
neurites2. It was previously thought that fibrils were the only
pathogenic α-syn species within LBs in the midbrain of PD
patients, but several lines of research have shown that α-syn
oligomers are also important in PD pathogenesis3. Molecular
tweezers have shown potential for tackling pathological protein
aggregation4,5. These compounds inhibit key interactions in the
self-assembly of amyloidogenic protein by binding to positively
charged amino acid residues and disrupting both hydrophobic
and electrostatic interactions. Specifically, the molecular tweezer
CLR01 binds to lysine residues crucial for α-syn oligomerization
and aggregation6. CLR01 has been shown to inhibit α-syn
aggregation in cell lines and zebra fish7, and, interestingly, to be
neuroprotective in a triple transgenic Alzheimer’s disease mouse
model8. There is still a lack of thorough translational studies of
neurodegenerative therapeutic approaches combining state-of-
the-art models, such as induced pluripotent stem cell (iPSC)-
derived dopaminergic cultures, humanized transgenic animal
models, and animals inoculated with PD brain extracts.
iPSC-derived dopaminergic cultures have been shown to
recapitulate midbrain development, and neurons survive in vivo
and integrate into Parkinsonian cellular networks9. Using iPSC-
derived dopaminergic cultures, we have detected cellular disease
phenotypes that recapitulate findings from post-mortem PD
cases10,11. We have also shown previously that expressing the
complete human SNCA locus as a transgene in mice on a Snca−/−
background recapitulates the spatial and temporal expression of
the endogenous human α-syn12. Transgenic animals exhibit age-
dependent motor behavioral phenotypes, dopaminergic cell loss,
as well as deficits in dopamine neurotransmission. We have also
previously demonstrated that LB-containing fractions of Parkin-
sonian brains can be isolated, and that injection of this purified
material into the SN of wild-type (WT) mice recapitulates Par-
kinsonian degeneration of dopaminergic neurons after 4 months
with α-syn aggregation spreading into connected areas of the
brain13.
In this study, we show that CLR01 reduces both the aggrega-
tion of recombinant α-syn and dissociates pre-aggregated α-syn.
We show that CLR01 reduces α-syn aggregation in LB extracts
from PD patients in vitro. iPSC-derived dopaminergic cultures
insulted with LB extracts show shortening and blebbing of their
processes, which is rescued by CLR01 treatment. In microfluidic
chambers, CLR01 also reduces α-syn aggregation and transport.
Our in vivo results show that CLR01 rescues motor behavior
defects and reduces α-syn aggregates and accumulation of α-syn
oligomers in the SN of SNCA transgenic animals dosed at
12 months, but not at 6 months, and only partially at 18 months.
These data indicate that the timing of treatment within a ther-
apeutic time window is critical when considering CLR01 for use
in the clinic. Finally, CLR01 reduces pathology in two different α-
syn injection models, namely an LB-injection model and a pre-
formed fibril injection model, demonstrating broad therapeutic
potential.
Results
CLR01 impairs α-syn aggregation in vitro. CLR01 binds spe-
cifically with high on–off rate to lysines and, therefore, its
specificity is not to a particular protein but to the process of
abnormal protein self-assembly itself. CLR01 has been shown to
be suitable for a high therapeutic dosing window in rodent
models that tolerate high doses of this compound well14. These
data highlight the need to investigate the anti-aggregation and
neuroprotective effects of this molecule further, to determine
whether it is promising as a disease-modifying treatment for PD.
To test whether CLR01 was able to have an impact on recom-
binant α-syn aggregation in vitro, we performed an electron
microscopy (EM) time-course of recombinant α-syn aggregation.
Recombinant α-syn was shaken at 250 r.p.m. and 37 °C for 1, 2, 3,
4, 5, and 10 days in the presence or absence of CLR01. In the
absence of CLR01, recombinant α-syn aggregated, forming both
fibrils and amorphous structures representative of oligomers,
whereas in the presence of CLR01 aggregation was severely
impaired (Supplementary Fig. 1A). We then evaluated whether
CLR01 could reduce the aggregation of recombinant α-syn pre-
formed oligomers and fibrils. Recombinant α-syn species were
incubated in the presence or absence of CLR01 for a further
10 days and then evaluated by EM. CLR01 reduced the presence
of oligomers and fibrils in these preparations (Supplementary
Fig. 1B), which is in agreement with the effects of CLR01 on
recombinant α-syn species previously shown by Prabhudesai
et al.7. We then tested whether CLR01 could reduce the presence
of aggregates in LB extracts from PD patients, which were pro-
duced as previously described13,15,16. LB extracts and their cor-
responding non-LB (noLB) control extracts were subjected to the
α-syn proximity ligation assay (AS-PLA) and EM to evaluate the
presence of oligomers17,18 and the morphology of the aggregates
(Supplementary Fig. 2), respectively. We have previously shown
that we can detect α-syn oligomers with AS-PLA, which α-syn
oligomers accumulate in the human where LB pathology is barely
detectable17, and that oligomeric deposition can be modulated18.
Here we found that α-syn oligomers could only be detected in
untreated LB extracts but were no longer detected when treated
with CLR01 for 10 days (Supplementary Fig. 2A–C). We could
also only find structures resembling LBs in LB extracts by EM
(Supplementary Fig. 2D), which were greatly reduced upon
incubation with CLR01. In summary, CLR01 inhibited α-syn
aggregation and caused dissociation of both oligomeric and
fibrillar α-syn.
α-Syn aggregation and toxicity are reduced by CLR01 in
human dopaminergic cultures. We initially explored the effects
of CLR01 and CLR03 (an inactive analog) in cell lines. We
transfected neuroblastoma SH-SY5Y cells with a plasmid over-
expressing α-syn and measured the resulting AS-PLA signal
(Supplementary Fig. 3A). Cells expressing the plasmid accumu-
lated high amounts of intracellular α-syn oligomers and were
treated by the addition of CLR01 to evaluate its ability to pene-
trate cells and to determine an EC50 for the compound. We found
that CLR01 was able to efficiently dissociate oligomers and/or
prevent their aggregation with an EC50 of 85.4 nM (Supplemen-
tary Fig. 3B, C) but that CLR03 did not have a significant effect on
the aggregation status of α-syn. To further explore the therapeutic
potential of CLR01, we next tested its ability to reduce α-syn
aggregation and toxicity in iPSC-derived dopaminergic neuron
cultures. Treatment with LB or noLB extracts produced different
surface textures upon microscopic inspection. Whereas we could
observe clear neuronal cell cultures in control and noLB samples,
LB-treated cells exhibited an abnormal texture indicating
deposition of putative proteinaceous material on the cell surface
(Fig. 1a and Supplementary Fig. 4A). However, when pretreated
with CLR01, this material or texture disappeared. The number of
dead cells labeled by To-pro was unchanged after incubation of
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brain extract with CLR01 (Fig. 1a and Supplementary Fig. 4A, G,
I). As a next step, we evaluated the levels of α-syn oligomers in
the culture and the number of tyrosine hydroxylase (TH)+ cells
(Fig. 1b–c and Supplementary Fig. 4B–C, H, J). The number of
TH+ cells was unchanged but we detected an upregulation of AS-
PLA puncta in LB-treated cells, which was reduced by 10 days of
10 µM CLR01 pre-treatment. Finally, as axonal degeneration has
been shown to precede cell death in PD19, we analyzed processes
labeled by the Tuj1 antibody to βIII-tubulin (Fig. 1d–f and
Supplementary Fig. 4D–F). NoLB extracts did not affect process
length or blebbing, whereas LB extract treatment shortened
neuronal processes and increased blebbing, which was reduced by
CLR01 pre-treatment back to control levels. This indicated that
LB extract treatment caused axonal degeneration of iPSC-derived
dopaminergic cultures, whereas CLR01 rescued the neurons
from these toxic effects. Finally, we exposed iPSC-derived dopa-
minergic cultures to LB extracts pretreated with increasing







































































































CTRL LB LB + CLR01













LB LB + CLR01
CTRL LB LB + CLR01
Fig. 1 CLR01 reduces α-syn aggregation and toxicity in iPSC-derived dopaminergic and primary rat cortical cultures. a, c, e Representative brightfield
and immunofluorescent images of live and dead cells (labeled by To-pro), dopaminergic cells (TH-positive), AS-PLA (red puncta), and neuronal processes
of four independent control cell lines analyzed. Cells were treated with LB extracts, which had been pretreated with CLR01 or PBS as a negative control. LB
treatment caused an abnormal deposition of material in treated wells, accompanied by increased AS-PLA signal process degeneration, which were reduced
by CLR01 pre-treatment. Scale bars= 100, 25, 25 µm, respectively. b, d, f Quantification of indicated parameters (from c and e) of four independent control
cell lines analyzed using a one-way ANOVA (Sidak’s). b F(2, 9)= 5.154, p= 0.0213. d F(2, 9)= 7.309, p= 0.0112, p= 0.0356. f F(2, 9)= 10.67, p=
0.0038, p= 0.0126. g, i Representative images of neuronal (top) and astrocytic (bottom) primary rat cultures stained with DAPI (n= 3 independent
cultures and treatments). Scale bars 20 µm. h, j Quantification of apoptotic cells (expressed as % from total) analyzed using a one-way ANOVA (Sidak’s,
n= 3 independent cultures and treatments). k F(2, 6)= 35.09, p= 0.0005, p= 0.0012. *p < 0.05, **p < 0.01, ***p < 0.001. For all appropriate panels, data
are presented as mean values ± SEM. BF brightfield, Norm normalized.
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CLR01 showed a dose-dependent reduction of α-syn oligomers in
dopaminergic cultures whereas CLR03 had no effect (Supple-
mentary Fig. 5A, B).
To test whether CLR01 could reduce α-syn aggregation and
toxicity in other neural populations, we treated primary rat
neuronal and astrocytic cultures with LB extracts in the presence
or absence of CLR01 (Fig. 1g–j). LB treatment induced cell death
in the neuronal cultures, but not in astrocytes, in agreement with
our previous findings20, and these effects were prevented by
CLR01 treatment. Altogether, these data suggest that CLR01 is
able to reduce α-syn aggregation and toxicity in human iPSC-
derived dopaminergic cultures and primary rat cultures.
CLR01 prevents α-syn aggregation in microfluidic chambers.
To investigate how α-syn is taken up and transported, we used
microfluidic chambers that allow axonal separation of two dis-
tinct cellular populations. As depicted in Fig. 2a in our first
experiment, we plated cells on both sides, the home and the insult
chamber, and kept the medium flow at all times towards the
insult chamber. This flow system prevents any passive diffusion
occurring from the insult chamber to the home chamber, there-
fore allowing us to determine that, if any insult is detected in the
home chamber, it would have been transported along an axon
(either by anterograde or retrograde transport). AS-PLA showed
that when we insult iPSC-derived dopaminergic cultures with
recombinant α-syn oligomers in the insult chamber, we can detect
this insult in the home chamber, indicating that oligomers are
actively transported along the axons of these cells (Fig. 2b). In the
presence of CLR01, the level of AS-PLA signal is greatly reduced
in the home chamber, indicating that CLR01 treatment protects
neurons from an oligomeric insult. To test whether there was a
specific involvement of retrograde transport in this process, we
examined the same paradigm without seeding cells in the insult
chamber (Fig. 2c). If an insult is detected in the home chamber in
the absence of cell bodies in the insult chamber under the same
flow conditions, the insult must have been transported by axonal
retrograde transport. Upon recombinant α-syn oligomer insult at
the terminals, we detected an increase in AS-PLA in the dopa-
minergic neuron cell bodies in our cultures (Fig. 2d), which
indicated that oligomers are moved by retrograde transport.
Application of CLR01 reduced the levels of AS-PLA seen after α-
syn oligomer insult.
We therefore decided to study whether α-syn interacted with
retrograde and anterograde transport proteins (dynein and
kinesin, respectively) through PLA, and whether these interac-
tions could be inhibited by CLR01. α-syn-dynein-PLA revealed
that dynein does interact with α-syn, and that this interaction can
be increased by insulting dopaminergic cultures with α-syn
monomers, which is then reduced by CLR01 treatment
(Supplementary Fig. 6A, B). When we examined the interactions
between α-syn and kinesin through α-syn-kinesin-PLA we could
detect a clear upregulation of the signal upon α-syn monomer
insult, which was depleted with CLR01 treatment. This indicates
that CLR01 is able to reduce this interaction and therefore
influence α-syn transport (Supplementary Fig. 6C, D).
In summary, these data show that recombinant α-syn
oligomers are actively transported along axons. Importantly,
CLR01 reduces α-syn oligomeric pathology following active
transport efficiently in iPSC-derived dopaminergic neurons and it
is specifically able to reduce interaction of α-syn with axonal
transport proteins.
CLR01 reduces α-syn aggregation and its detrimental effects
in vivo. Our laboratory has previously described a human α-syn-
overexpressing mouse model (SNCA-OVX), which showed
accurate spatial and temporal expression of human α-syn in a
mouse Snca-null background. Overexpression of α-syn in this
humanized model led to age-dependent neuronal loss, impaired
dopamine release, altered vesicle clustering, and motor defects12.
Here we conducted further analysis and found that, although
SNCA-OVX mice do not show pronounced whole-brain gliosis,
the SN has increased levels of GFAP (glial fibrillary acidic pro-
tein, astrocytes) and a shift in morphology for microglia (Iba1-
positive cells) (Fig. 3a–d and Supplementary Fig. 7). Microglial
cells in the SN are preferentially ramified (homeostatic) in WT
animals, yet microglia of SNCA-OVX animals adopt a more
ameboid morphology, which is suggestive of an activated state.
We have reported previously that these animals do not exhibit
LB-like aggregates; however, here, by using our recently devel-
oped AS-PLA assay17,18, we detected α-syn oligomers (Fig. 3e–f).
We detected a significant age-dependent accumulation of α-syn
oligomers, which likely is linked to the motor defects detected.
We therefore decided to use the SNCA-OVX model to test
whether CLR01 treatment could affect these phenotypes in vivo.
Mathematical in silico models have been previously used to
predict and model pharmacological and biological processes21–24.
We first administered radiolabeled CLR01 systemically to 12-
month-old animals to measure the blood–brain penetration of the
compound to inform an in silico model that would allow us to
determine whether a monthly dose of 40 µg/kg/day, which was
previously used8, would provide favorable pharmacokinetic
profile in the brain. The proportion of CLR01 in the brain was
determined as the percentage of radioactivity in the perfused
brain, relative to that of the blood, at three different doses and
three time points in 12-month-old animals. Our results indicate
that 10–35% of the drug concentration available in the blood is
present in the brain, and that this is a time- and dose-dependent
process (Supplementary Fig. 8A). Based on these data and
previously published blood kinetics14, we first predicted the extra-
and intracellular accumulation of the compound in the brain
(Supplementary Fig. 8B), then simulated a 2-month treatment
spread across 16 subcutaneous injections at 40 µg/kg/day
(Supplementary Fig. 8C), to obtain pharmacokinetic parameters
(Supplementary Table 1). We found that the intracellular time
averaged area under the curve was 240 ng/ml, with a predicted
maximum concentration of 510 ng/ml, which resulted in cells
being 93% of the experimental time above the EC50 (85.4 nM).
The model predicted a rapid intracellular accumulation of CLR01,
which lead to lower concentrations and time over EC50 in the
extracellular space, which were still above EC50 levels and
generally high (extracellular time averaged area under the curve
was 100 ng/ml, maximum concentration was 230 ng/ml, and time
above the EC50 was 81%). This simulation showed that CLR01
would be available at therapeutically relevant concentrations in
the extracellular space and the intracellular compartment of
the brain.
We then treated transgenic animals with CLR01 using three
different paradigms (Supplementary Fig. 9) as follows: first, 4-
month-old mice were injected for 2 months subcutaneously, then
12-month-old mice were subcutaneously injected for 2 months,
and, finally, 18-month-old animals were treated with a sub-
cutaneous implant of an osmotic mini-pump, to minimize
manipulation and stress of aged animals. As an end-point for
our 12- and 18-month cohorts, we assessed the animals for both
motor behavior and neuropathology, whereas the 6-month-old
cohort was evaluated for dopamine release and microglial
morphology. The 6-month cohort would be too young to show
a neuronal-loss-associated motor phenotype, considering our
previous findings12.
We treated 6-month-old animals to assess whether treatment
at an early timepoint was able to change early phenotypes, which
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may be linked to α-syn overexpression rather than α-syn
aggregation. At 6 months, dopamine release evoked by discrete
electrical stimuli in the striatum in acute slices as measured by
fast-scan cyclic voltammetry (FCV) was unchanged (Supplemen-
tary Fig. 10A, B). Likewise, we could not detect a difference in α-
syn oligomers in dopaminergic cells or microglial morphology
(Supplementary Fig. 10C–F), precluding testing treatment effect
in these young mice.
These results prompted us to treat older mice to assess whether
they would show the expected deficits and allow measurement of
neuroprotection, leading to a rescue of motor function. The 12-
month-old SNCA-OVX mice showed motor deficits in the latency
to fall on a rotarod and speed in catwalk analysis, which was
rescued by a twice-weekly subcutaneous injection of CLR01
(Fig. 4a, c), which was accompanied by restorative trends for
several other motor phenotypes (Fig. 4b, d and Supplementary
Fig. 11). Stool analysis, locomotor activity (LMA), and muscle
strength and coordination were unaffected by the treatment
(Supplementary Fig. 11). To test whether these effects were
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Fig. 2 CLR01 prevents α-syn aggregation in microfluidic chambers. a, c Schematic representation of the experimental design for the microfluidic-chamber
experiments. b, d Representative immunofluorescence images of dopaminergic neurons grown in the microfluidic devices insulted with oligomers and/or
treated with CLR01 for 5 days (25 µg/ml and/or 10 µM, respectively). Images were taken at least one field of view away from the microgrooves to avoid
artifacts due to contact with the silicone. Scale bars= 25 µm. Quantification of normalized puncta per field of three independent control cell lines analyzed
using a one-way ANOVA (Tukey). Oligo: oligomer. b F(2, 6)= 24.31, p= 0.0009 and F(2, 6)= 39.09, p= 0.0005, p= 0.0006. d F(2, 6)= 71.45. *p <
0.05, **p < 0.01, ***p < 0.001. For all appropriate panels, data are presented as mean values ± SEM.
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and SNCA-OVX animals with the same dose and paradigm as
above and subjected them to rotarod and catwalk analysis. Wt
animals showed no changes in their behavior after CLR01
treatment as measured by both rotarod and catwalk (Supple-
mentary Fig. 12), whereas a trend for improvement (which did
not reach significance probably due to smaller sample size) was
seen in the SNCA-OVX animals, suggesting that CLR01 may
require the presence of aggregates to elicit its effects. We also
observed a significant reduction in α-syn oligomers in dopami-
nergic SNc cells, and a reduction in GFAP staining (Fig. 4e–h).
Interestingly, the morphology of microglia shifted further towards
ameboid rather than ramified (Fig. 4i, j), which could be due to a
shift towards a phagocytic phenotype to clear the debris generated
by CLR01 treatment. Overall, we found that twice-weekly CLR01
injection is able to restore motor behavior and downregulate
oligomeric deposition as well as astrogliosis.
Finally, we decided to test the effects of CLR01 treatment in 18-
month-old animals. We could not detect any changes in the
behavior or stool analysis of 18-month-old animals carrying a
surgically implanted mini-pump releasing CLR01 at a constant
rate of 0.11 µl/h (Supplementary Fig. 13). However, we did detect
a significant reduction in the number of α-syn oligomers per
dopaminergic neuron in the SNc as shown in Fig. 5a, c. This
prompted us to investigate whether the treatment had impacted
the astrocytic and microglial populations of the SN. We could not
detect any changes in the GFAP-positive area or the morphology
of Iba1-positive cells in the SN of CLR01-treated animals
(Supplementary Fig. 14A–C). These results were unsurprising,
as by 18 months SNCA-OVX mice have lost ~30% of their SNc
dopaminergic neurons and, therefore, a rescue in motor behavior
or astrogliosis would be difficult to achieve after neurons are lost.
However, CLR01 was able to reduce the α-syn oligomer burden in
SN astrocytes and microglia (Fig. 5b, e), and to significantly
elevate the levels of PGC1α and Lamp2A in the midbrain of these
animals (Fig. 5f, g), but not those of Lamp1 (Supplementary
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Fig. 3 Glial activation and α-syn aggregation in SNCA-OVX mice. a, c, e Representative images of immunofluorescence of GFAP (astrocytes), IBA1
(microglia), and AS-PLA in dopaminergic neurons, respectively. Scale bars= 200, 25, and 25 µm, respectively. b, d, f Quantification of normalized stained
area, morphology (expressed as a % from total), and puncta per TH+ cell analyzed using a two-way ANOVA (Dunnett’s for age and Sidak’s for genotype,
for age all values compared to 3 months), n= 3–4 animals per group. b F(3, 20)= 1.211, p= 0.0177 for age and F(1, 20)= 0.1572, p= 0.0106 for genotype.
d F(1, 22)= 2.216, p= 0.0287 for genotype and F(3, 22)= 1.764, p= 0.0209, p= 0.0104, p= 0.0192 for age. f F(3, 21)= 4.528 for age, p= 0.0058, p=
0.0016, p= 0.0024 and F(1, 21)= 33.41, p= 0.0043, p= 0.0015, p= 0.0061 for genotype. *p < 0.05. For all appropriate panels, data are presented as
mean values ± SEM. OVX: SNCA-OVX.
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master regulator that plays a role in mitophagy and reactive
oxygen species (ROS) reduction, often perturbed in PD25;
Lamp2a is involved in chaperone-mediated autophagy (CMA)
and has been shown to be reduced in post-mortem PD brains26. It
is interesting to hypothesize that CLR01 might be able to
unburden TH+ cells from oligomeric α-syn, thereby indirectly
enabling mitochondrial turnover and ROS reduction, and
restoring CMA function, which are decreased with aging and
disease25,27,28. Finally, we confirmed the impact of CLR01
treatment on α-syn aggregates by evaluating midbrain levels of
Triton X-100 and SDS-soluble and -insoluble fractions of α-syn.
SNCA-OVX showed no signs of SDS-insoluble aggregates (which
agrees with the detection of oligomeric pathology), with most of
their α-syn content detectable in the Triton X-100 fraction
(Fig. 5h, i and Supplementary Fig. 14E). However, a small fraction
of α-syn was present in the SDS-soluble fraction in the midbrains
of SNCA-OVX animals, which was reduced by CLR01 treatment.
In conclusion, CLR01 treatment downregulated SN α-syn
oligomers and upregulated neuroprotective markers at 18 months


















































































































































Fig. 4 CLR01 restores motor behavior and reduces early pathology in vivo at 12 months of age. a–d Behavior analysis of rotarod (a) and catwalk gait
analysis (b–d) after 2 months of subcutaneous administration of 40 µg/kg/day drug or PBS analyzed using a one-way ANOVA (Sidak), n= 11–14 animals
per group. e, f Representative images and quantification of AS-PLA puncta per TH+ cell. Scale bars= 25 µm. g–j Representative images and quantification
of GFAP-stained area per field and microglial morphology (expressed as a % from total). Scale bars= 100 and 50 µm, respectively. a–j were analyzed using
one-way ANOVA (Holm–Sidak), e–j n= 8/8. CLR: CLR01 *p < 0.05, **p < 0.01. a F(2, 35)= 4.138, p= 0.0376, p= 0.0205. b F(2, 37)= 4.000, p=
0.0058. c F(2, 38)= 4.884, p= 0.0078, p= 0.0451. d F(2, 38)= 3.982, p= 0.0151. f F(2, 19)= 6.057, p= 0.0072, p= 0.0338. h F(2, 21)= 8.797, p=
0.0091, p= 0.0012. j F(2, 23)= 4.750, p= 0.0106. For all appropriate panels, data are presented as mean values ± SEM.
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Taken together, these results highlight that CLR01 effects are
age-dependent and likely linked to α-syn oligomerization and
aggregation, which increase with age, rather than to α-syn
overexpression itself.
CLR01 reduces α-syn aggregation after intracranial aggregate
injection. We tested whether CLR01 could reduce protein
pathology using two different intracranial injection models
(Supplementary Fig. 9), representing more late-stage pathology
than that of SNCA-OVX mice, which are a model for early oli-
gomeric accumulation of α-syn. First, we used a recombinant
mouse α-syn pre-formed fibril (mPFF) injection model, which
was previously described by Luk et al.29. We injected 3-month-
old C57Bl/6 WT mice with mPFF preparations in the dorsal
striatum and then followed pathology in the SNc of these mice.
Upon inspection of the SNc, lesions labeled by phospho-α-syn
were found to be more prevalent in the SNc than in the ventral
tegmental area, as was expected following dorsal striatum injec-
tion (Supplementary Fig. 15A–D). Subcutaneous injections of
CLR01 twice-weekly reduced the number of lesions in the SNc
compared to animals treated for a month with phosphate-
buffered saline (PBS) (Supplementary Fig. 15A, B).
We next tested whether CLR01 could reduce pathology
induced by the injection of LB extracts as described by Recasens
et al.13. LB extracts were injected into the SN of 4-month-old
C57Bl/6 WT mice, which were aged for a further 3 months before
CLR01 treatment. As these extracts are toxic and can lead to
neurodegeneration, we decided to implant an osmotic mini-
pump to deliver either PBS or CLR01 for the last month to
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Fig. 5 CLR01 reduces α-syn aggregation in vivo at 18 months of age. a–e Representative images and quantification of AS-PLA puncta per TH+, GFAP+,
and Iba1+ cells after osmotic mini-pump implantation of 40 µg/kg/days CLR01 or PBS, analyzed using a two-tailed t-test, n= 3/4 independent animals.
Scale bars= 50 µm. c p= 0.0117, d p= 0.0319, e p= 0.0179. f, g Western blottings of PGC1α and Lamp2a, analyzed using a one-tailed Mann–Whitney
U-test, n= 3–4 independent animals. f p= 0.0286, g p= 0.0286. h, i Native western blottings of Triton X-100 and SDS-soluble α-syn, analyzed using a
one-tailed Mann–Whitney U-test, n= 3–4 independent animals. i p= 0.0286. *p < 0.05. AV average, CLR CLR01. For all appropriate panels, data are
presented as mean values ± SEM.
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densitometry analysis showed that CLR01 treatment was able to
rescue TH+ immunoreactivity in the SN and striatum,
respectively (Fig. 6a–d). Nissl+ cell counts in the SN and DAT
in the striatum were only partially restored (Supplementary
Fig. 15E, F). Further analysis of the midbrains of these mice
showed that there was a reduction in α-syn PK-resistant puncta
and a reduction of staining by the Syn-F1 antibody, which are
indicators of a reduction of aggregated α-syn (Fig. 6e, h).
Discussion
Neuroprotective therapies targeting α-syn in PD have a high
potential for translation to patients in the clinic. Working across a
range of human in vitro and rodent in vivo α-syn-based models of
PD, we have shown that CLR01 reduces α-syn aggregation and
alleviates disease-related phenotypes. CLR01 dismantles synthetic
oligomeric and fibrillar, and patient LB-derived α-syn, alleviating
their toxic effects in vitro, reducing neurodegeneration-associated
α-syn accumulation in vivo, and correcting behavioral pheno-
types in a transgenic mouse model of PD.
Applying patient LB extracts treated with CLR01 to the highly
physiological human iPSC-derived dopaminergic cultures in vitro
gives a fully humanized model of disease. The LB extracts show a
higher α-syn oligomeric content than noLB extracts. CLR01
reduced the α-syn oligomeric content and with it the toxic effect
of the patient LB extracts. However, LB extracts likely contain
many other proteins30–32, which could be sensitive or resistant to
CLR01 treatment. When the extracts were applied to iPSC-
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Fig. 6 CLR01 protects dopaminergic neurons from LB-induced cell death through reduction of α-syn aggregation in mice. a, b Representative
photomicrographs of TH-immunostained SNc and striatum (respectively) in LB-inoculated mice after osmotic mini-pump implantation for CLR01 (or PBS)
delivery (40 µg/kg/h). c Stereological cell counts of SNc TH-immunoreactive neurons (a) in LB-inoculated mice, at 3 months post-LB inoculation. p=
0.0177. d Optical densitometry of striatal TH immunoreactivity in LB-inoculated mice (b), at 3 months post-LB inoculation. p= 0.0354. e, g Representative
photomicrographs of α-syn and PK-resistant α-syn immunostained SN from LB-inoculated mice, and corresponding quantification. f, h Representative
images of Syn-F1 immunostaining in the SN in LB-inoculated mice and corresponding quantification of the intensity levels of Syn-F1 staining. f p= 0.0333,
h p= 0.0556. a–h n= 4–5 for LB-inoculated mice, n= 5–7 for LB+ CLR01-independently treated animals, analyzed with a two-tailed Mann–Whitney U-
test. *p < 0.05. Scale bars= 0.1 mm (SN) and 1 mm (Str). For all appropriate panels, data are presented as mean values ± SEM.
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inhibits the toxic effects of LB extracts in both iPSC-derived and
primary neuron culture systems, as previously shown in the case
of Aβ-induced LTP defects in primary mouse hippocampal and
cortical neurons, and in an AD mouse model8.
Microfluidic chambers facilitate the isolation of axonal term-
inals from cell bodies in culture modelling pathology along the
neuron from synapse to soma. Several studies have shown that
degeneration may start in the striatal axons before affecting the
cell soma of dopaminergic neurons33. In support of this theory,
neuroimaging studies have shown that human PD presents early
with a larger loss of transporters and other DA axon markers in
the striatum than in the SNc34,35. As a result several groups have
studied this early degeneration in α-syn overexpression mouse
models and shown early striatal synaptic and dopamine release
defects prior to neurodegeneration12,36. It is therefore important
to investigate in vitro and in vivo whether the toxic effects of α-
syn on axon terminals can be alleviated with CLR01 adminis-
tration. Using microfluidic chambers in vitro, we observed that
CLR01 reduced the accumulation of α-syn oligomers in the cell
soma after treatment of axonal terminals, although it is possible
that this was in part due to an inhibition of retrograde transport
of α-syn, or to the minimal flow of CLR01-containing medium to
the insult chamber. In parallel studies in vivo, CLR01 adminis-
tration reduced lesions in dopaminergic cell somas in the SNc
after injection of mPFFs to the dorsal striatum, confirming a
protective effect of CLR01 against α-syn pathology in both axons
and cell bodies.
The age-dependent microglial and astrocytic activation in the
SNCA-OVX mouse model overexpressing α-syn supports a role for
inflammation in PD and other neurodegenerative disorders37–39.
The observation that microglial activation occurs in a time-
dependent manner almost simultaneously to oligomer deposition,
and that astrocyte activation is delayed in comparison, is consistent
with studies showing that astrocytic activation is induced by
microglial activation and is mediated at least in part by Il1α, TNF,
and C1q40. In SNCA-OVX mice at 6 months, the overexpression of
α-syn causes only mild oligomer accumulation and disease-related
motor phenotypes were not observed. The window for treatment
with a molecular tweezer is optimal at twelve months, when early
disease processes are underway and neuronal dysfunction has
begun, but before extensive and widespread dopaminergic neuron
degeneration. By 18 months, when dopaminergic neurons have
already been lost and neuroinflammation has been manifest for the
previous 6–12 months, inhibition of α-syn self-assembly by CLR01
is unable to reverse cellular and behavioral phenotypes. This
highlights the importance of studying the disease in a late-onset
age-dependent model and of treating the disease before it has
progressed beyond a putative point-of-no-return. Our work also
demonstrates that continuous administration, as used previously in
the rapidly-progressing Thy-1 α-syn overexpression model of
PD41, is unnecessary, further supporting the clinical development
of CLR01 in PD patients. We have also found that CLR01 is able to
elicit its function in the nanomolar range, which makes it a potent
compound that can be effective even at low doses, such as the ones
we use in vivo. These low doses showed promising predicted
pharmacokinetic properties in silico, which support previous
findings8,14 and our in vivo results.
Finally, to extend the application of CLR01 beyond transgenic
strains and to models of protein aggregate burden, we demon-
strated a positive therapeutic effect of CLR01 against α-syn-
induced pathology after intracranial injection of LB extract into
the SN. CLR01 treatment exhibited a neuroprotective effect
demonstrated by reduced α-syn pathology and a rescue of
dopaminergic neurons in the SNc and increased striatal TH+
innervation in the striatum. The positive effect of CLR01 in vivo
in both late-onset, age-dependent models, and in rapid models of
accelerated protein pathology demonstrates the robust applica-
tion of the molecule across diverse disease models.
We have investigated the broad utility of CLR01 against dif-
ferent forms of aggregated α-syn which complements previous
work on other amyloid assembly inhibitors. For example,
epigallocatechin-3-gallate (EGCG) has been shown to bind α-syn
inhibiting its aggregation42,43. It has also been shown to be pro-
tective in vitro44 and has shown promise by restoring MPTP-
induced neuronal loss45 and reducing peripheral immune
response after MPTP treatment46 in mouse models. The relatively
small size of CLR01 allows it to be internalized into cells as has
been shown in our study and by others47, providing an advantage
over antibody based therapies, which generally target external
epitopes, and are therefore unable to fully tackle toxic intracel-
lular α-syn species. Taken together, these data in diverse in vitro
and in vivo preclinical models suggest that molecular tweezers are
highly promising candidates for the treatment of PD.
Methods
Study design. Sample size was determined according to the experimental para-
digm. Sixteen animals were bread to account for loss of animals during ageing and
avoid n < 10 at the end of the study where behavioral differences of ageing cohorts
were investigated. Any animals showing any welfare issues were taken off the study,
otherwise animals remained in the sample. For neuropathological examination four
to five animals were bred per condition in order to avoid n < 3. For iPSC culture,
three to four independent control lines were used in order to ensure n ≥ 3. For
biochemical analysis of recombinant or biological material, three independent
experiments were performed on three independent samples.
Treatments were administered blindly by coding of the different groups into
numbers. Samples were blinded by taping over identifiers, to avoid bias when
sampling. For EM imaging, four independent fields were imaged and a
representative image was shown. For cell imaging, three to nine independent fields
of view were analyzed per well and one to two wells were analyzed per condition
and control line. For tissue analysis, two to four independent fields (i.e., at least 100
µm apart to avoid re-sampling) of anterior SN were analyzed, and for puncta
counts associated with TH+ cells, 25 neurons were sampled across the SNc. For
blood–brain barrier experiments, one radioactivity value was obtained per brain
and animal. For behavior and stereology, sampling is described in their particular
methods section.
Electron microscopy. Ten microliters of 0.2 mg/ml sample were applied to glow-
discharged, carbon-coated EM grids (TAAB). Samples were incubated for 2 min on
the grids at room temperature (RT), followed by 2% uranyl acetate staining for 10 s.
Samples were rinsed with water, dried, and stored at RT for analysis. Images were
acquired with a FEI Tecnai 12 transmission EM (120 kV) with a Gatan US1000
camera.
α-Syn aggregation. α-Syn (2 mg/ml; Peptide) were shaken at 37 °C and 250 r.p.m.
for as many days as described in each case, to induce aggregation of α-syn. To
produce oligomers, α-syn was shaken at 1 mg/ml and for 3 days (Supplementary
Fig. 16A).
PLA, immunofluorescence, and immunohistochemistry. AS-PLA experiments
were performed using the Duolink kits (Sigma) according to the manufacturer’s
instructions17,18. An α-syn antibody (mouse monoclonal anti-α-syn4D6, ab1903,
Abcam, 1:2000), was used to prepare conjugates using Duolink Probemaker
Plus and Minus kits. For α-syn-dynein and α-syn-kinesin interaction experiments,
we used the same α-syn antibody with monoclonal antibodies targeting dynein and
kinesin (mouse monoclonal anti-dynein MAB1618 and anti-kinesin MAB1614
from Millipore, respectively, both 1:100). For fluorescent AS-PLA of brain extracts
and cell samples, samples were fixed in 4% paraformaldehyde (PFA). All
samples were incubated with Duolink block solution at 37 °C for 1 h and then with
α-syn conjugates diluted in Duolink PLA diluent overnight (ON) at 4 °C.
Samples were washed with tris buffered saline (TBS) containing 0.05% Tween-
20 (TBS-T) and incubated with Duolink ligation reagents for 1 h at 37 °C,
washed four times with TBS-T, and then incubated with Duolink amplification
reagents for 2.5 h at 37 °C. Samples were washed and then mounted in FluorSave
(Calbiochem).
Paraffin-embedded tissue was dewaxed by 2 min consecutive incubations in
Xylene, Histoclear, 100% ethanol, 95% ethanol, 70% ethanol, and H2O. After
rehydration, samples were incubated in 10% H2O2 in PBS, to reduce background
and heated in a microwave in citrate buffer pH 6.0 (Abcam) for antigen retrieval.
After antigen retrieval, samples were subjected to immunofluorescence or AS-PLA
as necessary.
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For AS-PLA co-immunofluorescence, immunofluorescence was performed after
antigen retrieval and before PLA block. This process consisted of 1 h RT incubation
in 10% Serum TBS-T block, 1 h RT incubation in primary antibody (GFAP Z0334
Sigma 1:1000, Iba1 019-19741 Wako 1:1000, TH ab152 Millipore 1:1000, TH
ab76442 Abcam, 1:100, Tuj1 ab107216 Abcam, 1:100), after which slides were
washed with TBS-T. Slides then were incubated for 1 h at RT with secondary
antibodies (Alexa488, Alexa594, or Alexa680, Life Technologies), after which they
were washed again with TBS-T. If AS-PLA analysis was required, samples went on
to AS-PLA block, if not samples were mounted with FluorSave.
For recombinant protein analysis, 10 µl of 2 mg/ml samples were spotted on
poly-L-lysine coated cover slips, left at RT for 30 min, then PFA-fixed for 10 min,
and finally treated as above for fluorescent AS-PLA analysis.
Histopathological analysis of cryoprotected tissue. Extent of lesion: To assess
the integrity of the nigrostriatal pathway, TH immunohistochemistry was per-
formed on 50 µm free-floating SNc and striatal sections. Briefly, sections from three
representative levels of the striatum (anterior, medial and posterior) and serial
sections (1/6) corresponding to the whole SNc were incubated with a rabbit
monoclonal antibody raised against TH (Abcam, EP1532Y, 1:5000) for one night at
RT and developed with an anti-rabbit peroxidase EnVisionTM system (DAKO,
K400311) followed by 3,3′-diaminobenzidine (DAB) visualization. Free-floating
SNc sections were mounted on gelatinized slides, counterstained with 0.1% cresyl
violet solution, dehydrated, and cover-slipped, whereas striatal sections were
mounted on gelatinized slides and cover-slipped. The extent of the lesion in the
striatum was quantified by optical density (OD). Sections were scanned in an
Epson expression 10000XL high-resolution scanner and images were used in
ImageJ open source software to compare the grey level in the putamen. TH-positive
SNc cells were counted by stereology, blind with regard to the experimental con-
dition, using a Leica DM6000B motorized microscope coupled with the Mercator
software (ExploraNova).
α-Syn pathology: Synucleinopathy was assessed using a primary antibody that
recognizes both mouse and human α-syn (mouse anti-α-syn monoclonal antibody,
BD Transduction Laboratories, clone 42, #610787; BD Biosciences, SYN1, 1:1000)
and aggregated α-syn antibody (mouse anti-α-syn monoclonal antibody,
BioLegend, Syn-F1, 1:2000). In addition, SN sections were first incubated with or
without proteinase K (PK) at 1 μg/mL (Sigma-Aldrich) in PBS for 10 min at room
temperature13,48. PK-treated and nontreated adjacent sections then were incubated
ON at room temperature with SYN1 antibody, 1:1000. The following day, they
were incubated with a secondary antibody conjugated to a peroxidase EnVision
system (DAKO) DAB incubation. Sections then were mounted on gelatinized
slides, dehydrated, counterstained if necessary and cover-slipped until further
analysis. Images were used in ImageJ to count PK-resistant α-syn-positive dots in
SN (SYN1) or to measure OD in SN (Syn-F1). For striatal injections, tissue was
paraffin embedded and processed as specified above. The whole SN was sectioned
at 5 µm and every tenth section was stained for p-α-syn (EP1536Y, Abcam) and
TH (sc-25269, Santa Cruz). The sections with most p-α-syn+/TH+lesions were
blindly selected, and the resulting number of lesions was averaged for independent
animals.
Imaging. Samples were imaged with the Opera Phenix confocal microscope and
Harmony software (Perkin-Elmer) or the EVOSflAUTO (Thermo). For standard
cell culture, images were automatically captured with the Opera Phenix and ana-
lyzed with ImageJ or Cell Profiler for the detection of puncta (AS-PLA signal) or
cell nucleus/body (TO-PRO3, DAPI, TH counts), respectively. To analyze process
morphology, average length and number of puncta were analyzed. For microfluidic
and tissue samples, images were taken blinded to treatment on the EVOSflAUTO.
We used automatic measurement with ImageJ for puncta counts (AS-PLA signal)
or stained areas (GFAP signal). To count PLA puncta inside cells of interest, puncta
were counted blindly by eye in 25 cells per animal. In order to determine microglial
morphology, all microglial cells in the SN were clasified by a blinded operator by
eye as ramified or ameboid.
iPSC-derived dopaminergic cultures. iPSCs were cultured according to the
methods described in Supplementary Information and previous reports9,11,49.
NoLB and LB brain extracts were purified as described below and treated for
10 days ±10 μM CLR01 (Supplementary Fig. 16B) with continuous shaking at 37 °C
and 250 rpm. Cells were treated with 600 pg/ml noLB/LB extract ±10 μM CLR01 as
indicated on DIV36 and DIV38, and then harvested and measured on DIV41. To
culture cells in microfluidic chambers, dual axonal separation microfluidic devices
were purchased from Millipore and adapted for dopaminergic cell survival. Briefly,
the cell channel was carefully opened with a scalpel without disturbing the
microgrooves for axonal separation. The device was tested ON by leaving the
chambers filled with unequal volumes; if the volumes remained unequal after ON
incubation the chambers were used for experiments. For microfluidics assays,
CLR01 was used at 10 μM and oligomers were applied at 25 μg/ml.
For live-dead staining, TO-PRO-3 was added to culture medium 1:1000
(Thermo).
Neuroblastoma cell cultures. Neuroblastoma SH-SY5Y cell cultures were cul-
tured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine
serum (FBS), 1% penicillin/streptomycin, and 1% L-glutamine (Life Technologies)
at 37 °C and 5% CO2. On DIV0 cells were plated at 10,000 cells/well on half-area
96-well plates (Greiner). On DIV1 cells were transfected with a pcDNA3.1 vector
containing human α-syn (Addgene) with Lipofectamine 2000 and Plus reagent
(Life Technologies) in OptiMem (Life Technologies). On the next day, the medium
was changed to CLR03-/CLR01-containing medium. Plates were fixed on DIV4
and then processed for AS-PLA analysis.
Purification of LBs from human PD brains. The human brain samples were
obtained from brains collected in a Brain Donation Program of the Brain Bank
“GIE NeuroCEB” run by a consortium of Patients Associations: ARSEP (Asso-
ciation for Research on Multiple Sclerosis), CSC (cerebellar ataxias), France Alz-
heimer, and France Parkinson. The consents were signed by the patients
themselves or their next of kin in their name, in accordance with the French
Bioethical Laws. The Brain Bank GIE NeuroCEB (Bioresource Research Impact
Factor number BB-0033-00011) has been declared at the Ministry of Higher
Education and Research and has received approval to distribute samples (agree-
ment AC-2013-1887). Human SNc was dissected from fresh frozen post-mortem
striatal samples. Tissue was homogenized in 9 vol (wt/vol) of an ice-cold MSE
buffer (10 mM MOPS/KOH pH 7.4, 1 M sucrose, 1 mM ethylene glycol tetraacetic
acid, and 1 mM ethylenediaminetetraacetic acid) with protease inhibitor cocktail
(Complete Mini) with 12 strokes of a motor-driven glass/Teflon homogenizer. For
LB purification, a sucrose step gradient was prepared by overlaying 2.2 M with 1.4
M and finally with 1.2 M sucrose in volume ratios of 3.5:8:8 (vol/vol)50. The
homogenate was layered onto the gradient and centrifuged at 160,000 × g for 3 h
using a SW32.1 rotor (Beckman Coulter). Twenty-six fractions (500 µL each) were
collected from each gradient from top (fraction 1) to bottom (fraction 26) and were
analyzed for the presence of α-syn aggregates by a filter retardation assay as pre-
viously described13,51. LB-containing fractions from PD patients were those
between fractions 21 and 23. NoLB-containing fractions (i.e., fraction 3, at the
beginning of the 1.2 M interface) derived from the same PD patients (which
contain soluble or finely granular α-syn) but lack large LB-linked α-syn aggregates
were obtained from the same sucrose gradient purification. The amount of α-syn in
the LB fractions was quantified using a human α-syn ELISA kit (#KHB0061).
Further characterization of LB fractions was performed by immunofluorescence
analysis. Briefly, LB fractions from the sucrose gradient were spread over slides
coated with poly-D lysine and fixed with 4% PFA in PBS for 30 min. Fixed slides
were stained with 0.05% thioflavin S for 8 min and then washed three times with
80% EtOH for 5 min, followed by two washes in PBS for 5 min. Finally, all samples
were washed 3 times with PBS and blocked with 2% casein and 2% normal goat
serum for 30 min. For immunofluorescence analyses, samples were incubated with
a human α-syn-specific antibody (clone syn211, Thermo Scientific, 1:1000) for 30
min, washed three times with PBS, incubated with a goat anti-mouse TRITC-
conjugated antibody (Jackson, 1:500), before being cover-slipped for microscopic
visualization using fluorescence mounting medium.
Primary rodent cultures. Cortical neurons were obtained from the cortical lobes
of E18 Sprague–Dawley rat embryos: selected cortical tissue was digested with
0.25% trypsin and 0.004% deoxyribonuclease in Hank’s balanced salt solution
(HBSS; Sigma-Aldrich) for 5 min at 37 °C. The reaction was stopped by adding
Neurobasal medium (Invitrogen) supplemented with 10% FBS, B27 (Invitrogen), 2
mM glutamine, and antibiotic-antimycotic mixture, centrifuged at 1000 r.p.m. for
5 min, and the cell pellet was resuspended in 1 ml of the same solution. Mechanical
dissociation was performed by using 23-, 25-, and 27G-gauge needles, and the
resulting cell suspension was filtered through a 40 µm nylon mesh (Millipore)52.
Neurons were seeded onto poly-L-ornithine-coated glass cover slips (12 mm) at
10,000 cells/cm2. After 24 h, the medium was replaced with serum-free, B27-
supplemented Neurobasal medium and maintained at 37 °C and 5% CO2. The
cultures were essentially free of macroglia and microglia.
Primary cultures of cerebral cortical astrocytes were prepared from newborn
(P0–P2) Sprague–Dawley rats: cortical lobes were extracted and enzymatically
digested with 400 µl of 2.5% trypsin and 40 µl of 0.5% deoxyribonuclease in HBSS
for 15 min at 37 °C. The reaction was stopped by adding Iscoveʼs Modified
Dulbeccoʼs Medium (IMDM) supplemented with 10% FBS (Gibco) and
centrifuged at 1200 r.p.m. for 6 min. The cell pellet was resuspended in 1 ml of the
same solution and mechanical dissociation was performed by using 21- and 23G-
gauge needles53. After 2 weeks, cells were trypsinized and astrocytes were plated
(15,000 cells/cm2) onto poly-lysine-coated glass cover slips (12 mm).
Apoptosis assays. Rat astrocytes and neurons were plated respectively on poly-
lysine and poly-ornithine, and then treated with LB (120 pg/ml), CLR01 (10 µM),
or with the combination of LB and CLR01. Where indicated, LB was preincubated
for 10 days with 10 µM CLR01 in agitation before treating the cells. After 5 days of
incubation of the cells with the treatment, cells were fixed with 4% PFA and stained
with DAPI (Molecular probes). Images were taken with the Zeiss AxioVision
microscope. Apoptosis was calculated as a percentage of nuclei with condensed
chromatin vs. total nuclei.
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Transgenic animal cohorts. Transgenic SNCA-OVX mice were bred in house12,
while control animals C57/Bl6 were obtained from Charles River. All animals were
house in open top cages (five animals per cage maximum) at 21 °C, 55% humidity
in a 06:00 half-light, 07:00 on–18:00 half-light, and 19:00 off dark/light cycle. All
procedures were conducted in accordance with the United Kingdom Animals
(Scientific Procedures) Act of 1986 and approved by the local ethical review panel
at the Department of Physiology, Anatomy and Genetics, University of Oxford, or
in accordance with in accordance with the European Union directive of 22 Sep-
tember 2010 (2010/63/EU) on the protection of animals used for scientific pur-
poses, with approval from the Institutional Animal Care and Ethical Committee of
Bordeaux University (CE50, France) under the license number 5012099-A. Ani-
mals were age, sex, and weight matched.
Osmotic mini-pumps (model 1004 Alzet) were subcutaneously implanted on
the back of the neck of each 17-month-old animal. Briefly, animals were
anesthetized with 1–2% isoflurane and the pump was implanted through a minimal
incision, which was subsequently sutured. The pumps contained CLR01 in sterile
PBS (40 µg/kg per day) or PBS as a vehicle. After a month, mice went through
behavior testing.
Twelve- and 4-month-old animals were subcutaneously injected every Monday
and Thursday for 2 months. To achieve 40 µg/kg per day, the total amount required
for a given mouse for the 2 months was divided into 16 × 100 μl doses. After the
treatment was complete the mice went through behavior testing or FCV.
Tissues were harvested by cervical dislocation, dissection and flash freezing with
dry ice, or perfusion fixing with 4% PFA (Sigma). Fixed tissue was left in PFA ON
at 4 °C, and then transferred to 70% ethanol for an additional ON at 4 °C. The
tissue was dehydrated and included in wax through 1 h RT incubations as follows:
95% ethanol, 100% ethanol, 100% ethanol, Histoclear (National Diagnostics),
Histoclear, wax (Paraplast Plus, Sigma), wax and wax. Sections were then cut using
a microtome at 5 μm.
For blood–brain barrier penetration, experiments were performed according to
the procedures described in Attar et al.14. As subtraction of blood-born
radioactivity was proven to be as effective as perfusion, we used this method to
correct for blood-born radioactivity in the brain.
Animals and stereotactic Inoculations. Wild-type C57Bl/6 mice (4 months old)
received bilaterally 2 µl of human PD-derived α-syn (LB fractions, prepared as
described above13) by stereotactic delivery to the region immediately above the SN
(−2.9 mm anteroposterior, ±1.3 mm lateral, and −4.5 mm dorsoventral) at a flow
rate of 0.4 µl/min. Three months later, CLR01 was administered subcutaneously to
mice using osmotic mini-pumps for 28 days (40 µg/kg per day, Alzet Model 1004).
Filling, priming, and implantation of the pumps were performed using standard
protocols provided by the manufacturer. After 28 days of treatment, mice were
perfused transcardially with a 0.9% saline solution. Brains were removed quickly
after death and post-fixed for 3 days in 4% paraformaldehyde at 4 °C, cryoprotected
in PBS containing 30% sucrose, and stored at −80 °C until sectioning.
For striatal injections, WT, 3-month-old, C57Bl/6 mice received a 1.5 µl
injection of mPFF that had been previously sonicated for 1 min at bregma 0.5 mm
anteroposterior, −2.5 mm mediolateral, and 2.7 mm dorsoventral at a flow rate of
200 nl/min with a 32 gauge Hamilton syringe (Hamilton) that was withdrawn 5
min post injection. The mice were subsequently injected with
CLR01 subcutaneously every Monday and Thursday for 1 month. In order to
achieve 400 µg/kg per day, the total amount required for a given mouse for the
month was divided into 8 × 100 μl doses.
Behavior analysis and FCV. Spontaneous LMA was assessed by placing each
mouse in a transparent plastic cage, and assessing locomotion by means of infra-
red beam breaks over a 4 h period in 30 min intervals (apparatus manufactured by
San Diego Instruments). The floors of the cages were covered by a thin layer
bedding and measurements were started at 9:00.
To analyze gait, we used a CatWalk automated gait analysis system (Noldus
Information Technology). Mice were placed on a transparent glass platform
illuminated with green light on a red background. Runs were acquired and
accepted for analysis if they were between 0.5 and 5 s in duration and there was
<35% variation in speed. The first five compliant runs were analyzed with Catwalk
software, and the average data for each mouse was taken for analysis.
For rotarod analysis, mice were gently placed on an open rotarod (Med
Associates, Vermont, USA) facing away from the experimenter. Mice were tested
under the same accelerating conditions (4–40 r.p.m. over 5 min) for two
consecutive days starting at 9:00. The first day was considered acclimatization; on
the second day, the latency to fall was recorded for analysis.
For muscle strength and coordination analysis, mice were placed on a 43 cm2
wire mesh attached to a 4 cm deep wooden frame. After 5 s, the grid was carefully
inverted and the latency to fall was measured. After 60 s, the test was stopped, as
this was considered maximum score.
For stool collection animals were placed into separate clean cages with no access
to food or water, and fecal pellets were collected over a 1 h period (1600–1700 h).
Pellets were weighed to obtain wet stool weight, dried ON at 65 °C, and reweighed
to obtain dry stool weight and stool water content.
For FCV animals were culled by cervical dislocation and 300 µm coronal slices
were prepared for analysis in ice-cold artificial cerebrospinal fluid (aCSF). Samples
were maintained in aCSF saturated with 95% O2/5% CO2 and analyzed through
probing of the dorsal or ventral striatum with a carbon fibre microelectrode.
Electrical stimuli were single pulses, repeated at intervals of 2.5 min, delivered at
0.6 mA, for 200 µsec12. Data were acquired and analyzed with Axoscope 11.0
(Molecular Devices).
Western blotting. Dissected brain regions were lysed in RIPA buffer (SDS-poly-
acrylamide gel electrophoresis (PAGE)) or non-denaturing lysis buffer (native
PAGE). For immunoblot analysis, 10 μg of total protein per lane was loaded on
4–15% gels (Bio-Rad) and blotted onto polyvinylidene difluoride membranes (Bio-
Rad). For SDS-insoluble 0.5 μg of total protein was loaded. Blotted samples were
probed with antibodies against α-syn (MJFR1 Abcam), PGC1α (Santa Cruz Bio-
technologies sc-13067), Lamp2A (Abcam, ab18528) and Lamp1 (Abcam, ab24170),
all 1:1000. After ON incubation with primary antibody at 4 °C blots were washed in
TBS-T and incubated in secondary horseradish peroxidase antibody (Bio-Rad,
1:5000) for 1–2 h at room temperature. Blots were analyzed with enhanced che-
miluminescence reagents (Millipore) in a Chemidoc (Bio-rad). Beta-actin was used
as a loading control. Uncropped blots are available in the Source Data File.
Statistical analysis. Statistical analyses was performed with GraphPad Prism 6.0
(GraphPad Software). Two-way analysis of variance (ANOVA), one-way ANOVA,
t-test, and Mann–Whitney U-tests were used as required (specified in figure
legends). In all analyses, statistical significance was set at p < 0.05. Unless otherwise
stated, all error bars depict SEM. For ANOVA analysis, F is expressed as F (degrees
of freedom, degree of freedom error)= x.
In silico modeling of CLR01 pharmacokinetics. Supplementary Methods detail-
ing the in silico modeling of the pharmacokinetics of CLR01 are available. The code
for the model is available upon request.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this paper.
Data availability
Authors can confirm that all relevant data are included in the paper and/ or its
supplementary information files. The code for the pharmacokinetics modeling in the
brain is available upon request. Source data are available as a Source Data File. LR01 may
be obtained from G.B. Source data are provided with this paper.
Received: 9 May 2019; Accepted: 27 August 2020;
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